Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into Phase 2 testing for idiopathic pulmonary fibrosis. Mediar said it expects to ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target.

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...